Command Palette

Search for a command to run...

GLENMARK

1906-1.72%
Market Cap
₹54,725.79 Cr
Stock P/E
72.61
ROCE
16.16%
ROE
12.56%
Book Value
₹314.93

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

POSITIVES
  • Consolidated revenue grew 0.6% YoY in Q1 FY26, signaling resilience despite headwinds.
  • India Formulation growth outpaced the market; strong IQVIA signals and leadership in key therapy areas.
NEGATIVES
  • Near-term Europe revenue declined, with expectations of a rebound to double-digit growth in FY26.
  • LatAm headwinds due to seasonality dampened demand in Q1.

Peers Summary

Financially Stressed

Glenmark Pharmaceuticals Ltd. demonstrates significant challenges in growth and profitability metrics compared to its peers, exhibiting a decline in revenue and negative profit margins, which places it at a disadvantage in the competitive pharmaceuticals sector. This analysis highlights both the underperformance of Glenmark and identifies peer companies that exhibit stronger financial health and growth potential.

Key Points
  • Glenmark has a negative revenue growth YoY of -9.06% and a negative profit margin of -15.50%.
  • Highest EPS growth is observed in Dr. Reddy's Laboratories (68.07), while Glenmark's EPS is 37.10.
  • Cipla Ltd. leads in ROE with 16.63%, while Glenmark's ROE is significantly lower at 12.56%.
  • Glenmark's PE ratio of 33.79 suggests it is overvalued relative to peers with lower growth prospects.
  • With a debt-equity ratio of 0.2482, Glenmark is in a relatively stable position, but its profitability metrics are concerning.
Top Performers
Cipla Ltd.

Strong revenue growth (YoY: 13.28%) and the highest ROE (16.63%) among peers.

Dr. Reddy's Laboratories Ltd.

Excellent profitability with a PE of 15.50 and significant revenue growth.

Mankind Pharma Ltd.

Outstanding growth trajectory with a YoY revenue increase of 18.12% and strong financial metrics.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.